Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin

著录项

• 来源
  《British Journal of Haematology》 |2020年第3期|共5页
• 作者

  Cassaday Ryan D.; Marks David I.; DeAngelo Daniel J.; Jabbour Elias J.; Advani Anjali S.; OBrien Susan; Wang Tao; Neuhof Alexander; Vandendries Erik; Kantarjian Hagop M.; Stock Wendy; Stelljes Matthias;

  展开▼
• 作者单位

  Univ Washington Sch Med Seattle WA 98195 USA;

  Univ Hosp Bristol Bristol Avon England;

  Dana Farber Canc Inst Boston MA 02115 USA;

  Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

  Cleveland Clin Taussig Canc Inst Cleveland OH 44106 USA;

  Univ Calif Irvine Chao Family Comprehens Canc Ctr Irvine CA USA;

  Pfizer Inc Cambridge MA USA;

  Pfizer Pharma GmbH Berlin Germany;

  Pfizer Inc Cambridge MA USA;

  Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

  Univ Chicago Chicago IL 60637 USA;

  Univ Klinikum Munster Munster Germany;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 血液及淋巴系疾病;
• 关键词

  acute lymphoblastic leukaemia; inotuzumab ozogamicin; relapsed; treatment cycles; HSCT;

  机译：急性淋巴细胞白血病;inotuzumab ozogamicin;复发;治疗周期;HSCT;